SMARCA4-Deficient Tumor
specificA finding indicating that the expression of SMARCA4 in a tumor sample is aberrantly low or undetectable.
11
Centers
11
Active Trials
—
Cancer Funding
Top Centers for SMARCA4-Deficient Tumor(11)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 54.5 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 54.5 |
| 3 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 54.5 |
| 4 | NCI Comprehensive Active Research Program | 54.5 |
| 5 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 54.5 |
| 6 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 54.5 |
| 7 | NCI Clinical Active Research Program | 54.5 |
| 8 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 54.5 |
| 9 | University of Illinois Cancer CenterChicago, IL Active Research Program | 54.5 |
| 10 | Boston University Cancer CenterBoston, MA Active Research Program | 54.5 |
| 11 | Cancer Center at IllinoisUrbana, IL Active Research Program | 54.5 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →